Sponsor Dossier
Janssen-Cilag
Sponsor Dossier for Janssen-Cilag. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: CONCERTA
- Brand: DARZALEX
- Brand: DUROGESIC
- Brand: EDURANT
- Brand: EPREX
- Brand: ERLYAND
- Brand: IMBRUVICA
- Brand: INTELENCE
- Device (sponsor): Electric infusion pump administration set
- Device (sponsor): Infusion administration set, infusion pump
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
About
Janssen-Cilag is an Australian Private Company with ABN 47000129975, registered in New South Wales and currently active. The company operates under the trading names Johnson & Johnson Innovative Medicine and Johnson & Johnson Innovation.
Portfolio
Janssen-Cilag has 35 brands on the ARTG, of which 33 are indexable and 32 carry a Product Information document. 24 brands are PBS-listed, 25 have a PBAC outcome on record, and 17 have an AusPAR on record. Notable brands include CONCERTA, DARZALEX, DUROGESIC, EDURANT, EPREX, ERLYAND, IMBRUVICA, INTELENCE, INVEGA, JANSSEN, JAXIMAB, LAZCLUZE.
Therapeutic focus
— Oncology: 10 brands — Immunology: 6 brands — Infectious Disease: 5 brands — Psychiatry: 4 brands — Cardiology: 4 brands — Haematology: 2 brands — Pain Management: 1 brand — Neurology: 1 brand — Rare Disease: 1 brand — Gastroenterology: 1 brand
PBS footprint
24 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-07-01, across 25 brands with a PBAC outcome on record. The latest AusPAR is 2025-10-01, across 17 brands with an AusPAR on record.